27 February
2024
PureTech Health plc
PureTech to Present at Two Upcoming Investor
Conferences
PureTech Health
plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to changing the
lives of patients with devastating diseases, today announced that
members of the management team will participate at two upcoming
investor conferences. Webcasts of the presentations will be
available at https://investors.puretechhealth.com.
TD Cowen 44th Annual
Health Care Conference
Presenters: Daphne Zohar,
Founder and Chief Executive Officer, and Eric Elenko, Ph.D., Chief
Innovation Officer
Date: Tuesday, March 5,
2024
Time: 1:30 p.m. EST
Leerink Partners
Global Biopharma Conference
Presenters: Bharatt Chowrira,
Ph.D., J.D., President, and Eric Elenko, Ph.D., Chief Innovation
Officer
Date: Wednesday, March 13,
2024
Time: 10:40 a.m. EDT
About PureTech
Health
PureTech is a clinical-stage biotherapeutics
company dedicated to giving life to new classes of medicine to
change the lives of patients with devastating diseases. The Company
has created a broad and deep pipeline through its experienced
research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced
both internally and through its Founded
Entities. PureTech's R&D engine has resulted in the
development of 28 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received
both US FDA clearance and European marketing
authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various
indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by
the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains statements that are or
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our upcoming presentation at TD
Cowen's 44th Annual Health Care Conference, the Leerink Partners
Global Biopharma Conference, and our future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2022 filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the Company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
|
EU
Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
|
U.S.
Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com
|